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Catch-and-Release Probes Applied to Semi-Intact Cells
Reveal Ubiquitin-Specific Protease Expression in
Chlamydia trachomatis Infection
Jasper H. L. Claessen, Martin D. Witte, Nicholas C. Yoder, Angela Y. Zhu, Eric Spooner, and
Hidde L. Ploegh*[a]
Introduction
Protein ubiquitylation is a versatile post-translational modifica-
tion that regulates a wide array of biological processes, rang-
ing from trafficking of proteins and signaling cascades, to pro-
tein stability. Conjugation of ubiquitin (Ub) is achieved through
a cascade of enzymes. The C-terminal carboxylic acid of ubiqui-
tin is activated by an E1 ubiquitin-activating enzyme that uses
ATP to yield a ubiquitin-enzyme thioester. Transthioesterifica-
tion to an E2 ubiquitin-conjugating enzyme is followed by
transfer of ubiquitin to protein substrates through an E3 ligase.
The vast number of predicted E3 ligases (>600) allows for
great specificity. Multiple ubiquitylation reactions can occur on
the same protein, either as mono- or polyubiquitin modifica-
tions, the latter using structurally different linkages, to produce
a highly versatile protein modification system (reviewed in
ref. [1]).
Ubiquitylation is reversible. Protein trafficking, where depen-
dent on ubiquitylation, would require removal of ubiquitin
once the protein has reached its destination. Similarly, a ubiqui-
tin tag can mark proteins for proteasomal destruction, but
ubiquitin itself can be removed to recycle it. Deubiquitylating
enzymes (DUBs), also known as ubiquitin-specific proteases
(USPs), cleave ubiquitin from substrate proteins. The human
genome encodes ~80 (putative) DUBs, the majority of which
have a papain-like active site.[2] DUB activity is tightly regulated
by post-translational modifications, protein–protein interac-
tions, and subcellular localization, both to increase specificity
and for temporal control of ubiquitin removal.[3] Large-scale ef-
forts have allowed the construction of interaction maps of the
individual DUBs to gain insight in their physiological role and
regulation.[4] These efforts have thus far relied mostly on over-
expression of individual DUBs modified with affinity handles,
and subsequent retrieval of that particular DUB and its inter-
actors. However, this approach has been limited to a small
number of tissue culture cell lines and may suffer from artifacts
due to overexpression of a DUB or its catalytic domain. Elevat-
ed DUB levels can result in strong phenotypes, such as a com-
plete block in proteasomal degradation.[5]
Our laboratory has prepared activity-based probes (ABPs) for
the (de)ubiquitylation pathway to study in an unbiased
manner the enzymes involved in these reactions. This ap-
proach samples DUBs at their endogenous expression level,
and in their full-length active state. We equipped the C termi-
nus of influenza hemagglutinin (HA) tag containing ubiquitin
with a variety of electrophiles by aminolysis of protein thioest-
ers, prepared by the intein fusion method.[6,7] Recently, other
labs replaced the HA tag by fluorophores to create fluorescent
analogues of these probes.[8,9] These ubiquitin derivatives act
as covalent, cysteine-directed inhibitors of ubiquitin and ubiq-
uitin-like deconjugating enzymes, as well as of a subset of
ubiquitin ligases. The labeled enzymes can be visualized either
by immunoblotting or are identified by mass spectrometry
after affinity purification in the case of HA-tagged proteins[10]
and by in-gel fluorescence scanning in the case of fluorescent
probes.[8,9] Of the electrophiles tested, the vinyl methyl ester
Protein ubiquitylation controls many cellular pathways, and
timely removal of ubiquitin by deubiquitylating enzymes
(DUBs) is essential to govern these different functions. To map
endogenous expression of individual DUBs as well as that of
any interacting proteins, we developed a catch-and-release
ubiquitin probe. Ubiquitin was equipped with an activity-
based warhead and a cleavable linker attached to a biotin
affinity-handle through tandem site-specific modification, in
which we combined intein chemistry with sortase-mediated li-
gation. The resulting probe is cell-impermeable and was there-
fore delivered to the cytosol of perfringolysin O (PFO)-permea-
bilized cells. This allowed us to retrieve and identify 34 DUBs
and their interacting partners. We also noted the expression, in
host cells infected with Chlamydia trachomatis, of two addi-
tional DUBs. Furthermore, we retrieved and identified chlamy-
dial DUB1 (ChlaDUB1) and DUB2 (ChlaDUB2), demonstrating
by experiment that ChlaDUB2, the presence and activity of
which had not been detected in infected cells, is in fact ex-
pressed during the course of infection.
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(VME) derivative is probably the most broadly reactive warhead
with ubiquitin deconjugating[6] and conjugating[10] enzymes, ir-
respective of enzyme family or organism of origin.
Using these ABPs, we identified DUBs in mammalian cells
and those encoded by pathogens such as the Herpes viruses,
parasites including Plasmodium falciparum and Toxoplasma
gondii, and bacteria such as Chlamydia trachomatis.[11–13] Al-
though viral and bacterial pathogens do not possess an intact
ubiquitin pathway, they presumably express DUBs to evade de-
tection by the immune system or to otherwise enhance viru-
lence[14] especially for those pathogens with an intracellular
lifestyle. Detection of DUBs in the context of host infection can
be challenging, as expression levels can vary between infec-
tious agents and with the time of infection. Detection is there-
fore highly dependent on the sensitivity of the approach used.
An example is the bacterium C. trachomatis, for which no
means of genetic manipulation has been established to date.
We identified a single Chlamydial DUB (ChlaDUB1) using
UbVME probes,[11] but the Chlamydia genome also encodes a
second putative DUB, termed ChlaDUB2. Even though recom-
binantly expressed ChlaDUB2 encodes a UbVME-reactive pro-
tein, the actual product has escaped detection in the course of
a chlamydial infection.
We attribute this inability to a lack of sensitivity of the activi-
ty-based probes available at the time, and to the manner of
their application. Furthermore, in the course of affinity-based
purification, abundant, poorly soluble, or otherwise nonspecifi-
cally interacting proteins invariably accumulate on the affinity
matrix. Recovery of samples from the matrix under denaturing
conditions will then elute these contaminants together with
the specific interactors, resulting in false-positive hits during
mass spectrometric identification. Moreover, the presence of
background peptides adversely affects the bandwidth available
to detect true protein targets, in turn decreasing the limit of
detection of true positive hits.[15]
A second and more specific drawback of many such ABPs is
that they are cell-impermeable and therefore can be used only
in cell lysates. Lysis of cells usually entails massive dilution of
the cytosol, which in turn may lead to dissociation of protein
complexes with concomitant loss of activity, and reduced or
no binding of the ABP when the affinity of the target for the
ABP is low.
To mitigate the first issue, we equipped UbVME derivatives
with recently described chemically cleavable linkers.[16–18] These
linkers allow cleavage under mild conditions and enable specif-
ic retrieval of the tagged proteins while minimizing release of
nonspecific binders (Figure 1A). The second issue was ad-
dressed by developing a method that allows the delivery of
the probe to the cytoplasm of permeabilized cells (Figure 1B)
with minimal dilution of the target cytosol. The combined
methods allowed us to retrieve 34 DUBs—one of which had
not been previously identified by ABP. Two additional host
DUBs were detected in HeLa cells infected with C. trachomatis.
Furthermore, the covalent modification of DUBs with ABPs in
a less dilute cytosol and thus presumably a more physiological
setting resulted in retrieval of a large number of interacting
proteins, as identified using mass spectrometry. Finally, we
were able to detect ChlaDUB2, 24 h after infection of HeLa
cells with C. trachomatis, showing that this enzyme, the pres-
ence of which was previously inferred but never demonstrated
in Chlamydia-infected cells, is expressed.
Figure 1. An overview of the cleavable linker approach. A) DUBs are labeled with an ABP containing the cleavable linker. The labeled proteins are retrieved
on a streptavidin matrix which is then washed before release by selective cleavage of the linker. B) An overview of probe delivery approach. Cells are incubat-
ed on ice with perfringolysin O (PFO) in the presence of the probe. The cells are incubated at 37 8C for 30 min to allow pore formation and labeling to occur.
The cytosol is then separated from the cellular compartments by centrifugation.




Preparation and validation of catch-and-release ubiquitin
electrophiles
A ubiquitin moiety that carries diverse modifications at the
N terminus such as epitope tags, fluorophores, and biotin can
still be recognized by the ubiquitin conjugation and deconju-
gation machinery,[6, 9] whereas modification of the e-amino
group of its lysine residues might interfere with activity
through elimination of possible conjugation sites. Modifica-
tions at the C terminus might result in altered specificity.[19] We
therefore selectively introduced a cleavable linker at the N ter-
minus of UbVME using the sortase-based transpeptidation re-
action. This is a versatile and easily implemented site-specific
protein ligation strategy (Scheme 1). Proteins bearing 1–5 gly-
cine residues at the N terminus can be labeled using appropri-
ately functionalized LPXTG peptides.[20,21] We therefore synthe-
sized peptides 1–3 (Scheme 1), which combine previously re-
ported catch-and-release moieties[16–18] with the above peptide
sequence (for synthesis, see Schemes S1 and S2 in the Sup-
porting Information). Preliminary experiments showed that
protein recovery from the streptavidin resin was significantly
improved by extending the biotin handle using a polyethylene
glycol (PEG)-type spacer (Figure S1A). This scheme is generaliz-
able, in that it can be applied to any protein with a suitably
exposed run of Gly residues.
We prepared a derivative of ubiquitin vinyl methyl ester
(UbVME) as a nucleophile with three glycine residues append-
ed at the N terminus (G3UbVME).
[22] N-terminal sortagging of
G3UbVME with catch-and-release probes 1–3 proceeded in 50–
70% yield. Purification by RP-HPLC gave highly pure and la-
beled UbVME (Figure S1B and C). HPLC purification also al-
lowed for recovery from the reaction mixtures of unreacted
G3UbVME that could then be used in subsequent reactions,
thus minimizing losses of valuable input materials. This syn-
thetic strategy enables the production of a protein reagent
bearing two site-specific bioorthogonal chemical modifications.
Examples of this in the literature are scarce.[20, 23,24]
The activity of the different catch-and-release UbVME probes
was evaluated by reacting them with purified recombinant
ubiquitin carboxy-terminal hydrolase isozyme L3 (UCH-L3),
a well-characterized DUB.[25] Analysis of the reaction products
by anti-ubiquitin immunoblot revealed a ubiquitin-bearing
product at ~37 kDa, corresponding to the covalent adduct of
UCH-L3 (26 kDa) with biotin-labeled ubiquitin (~10 kDa). Bind-
ing of the reaction products on streptavidin, followed by expo-
sure of the streptavidin resin to the optimized cleavage condi-
Scheme 1. Preparation of cleavable linker-containing UbVME probes. G3UbVME was equipped with peptides 1–3 using a transacylation reaction catalyzed by
the bacterial enzyme sortase A (Srt A).
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tions for each cleavable linker, yielded the UCH-L3-UbVME
adduct in >50% recovered yield for all three derivatives
(Figure 2, left and middle lanes). Boiling of the streptavidin
resin in Laemmli sample buffer after chemical cleavage re-
leased only a minimal amount of residual protein (right lanes),
demonstrating the efficiency of cleavage.
Probe efficiency in whole cell lysate
The results of the in vitro assay using recombinant UCH-L3
prompted us to assess the efficiency of the catch-and-release
probes in whole cell lysates. HEK293T cells were cultured over-
night in the presence of [35S]cysteine/methionine to achieve
steady-state protein labeling.
The labeled cells were lysed in
NP40 lysis buffer. The lysate was
then precleared with streptavi-
din agarose to remove any en-
dogenously biotinylated proteins
prior to incubation with the
probe of choice (1 mm). Modified
proteins were retrieved using
streptavidin-agarose and were
specifically eluted through cleav-
age of the chemical linker (see
the Experimental Section). Final-
ly, the eluted proteins were sep-
arated by SDS-PAGE and visual-
ized using autoradiography (Fig-
ure 3A).
First, we retrieved few pro-
teins in the lanes where the
probe was omitted from the re-
action (lanes 1, 3 and 5). In con-
trast, addition of the probe and
subsequent chemical cleavage of
the linker resulted in the specific
retrieval of a large number of
proteins (lanes 2, 4 and 6), dem-
onstrating the added benefit of
the catch-and-release approach used here. The efficiency of re-
trieval varied between the three individual probes (Figure 3A),
most likely attributable to differences in cleavage efficiencies.
Whereas retrieval with the CLB probe proved rather poor,
a large number of specific proteins was retrieved with either
the LEV, or AZO probe, the latter slightly outperforming the
former.
The complex mixture of labeled DUBs and the interacting
partners that are recovered in this approach can complicate
data analysis. The mild chemical cleavage conditions are ex-
pected to yield, upon cleavage, native protein complexes with
the possibility of performing an immunoprecipitation (IP) for
a particular DUB of choice (and its interactors). To demonstrate
the feasibility of this approach, 293T cells were transiently
transfected with YOD1—a DUB involved in glycoprotein dis-
location from the endoplasmic reticulum (ER)—and treated as
described above.[26] After chemical cleavage, the eluted pro-
teins were diluted in NP40 buffer and subjected to IP with an
antibody against YOD1. When we analyzed the chemical
eluate by SDS-PAGE, we observed a complex banding pattern
with a prominent polypeptide at a molecular weight corre-
sponding to YOD1 modified with the ubiquitin probe (Fig-
ure 3B). The same polypeptide was observed also after
a second IP for YOD1, confirming its identity. We found that
the LEV probe, although slightly less efficient in the first set of
experiments (Figure 3A), performed better in this setting. Far
less protein was retrieved in a consecutive IP when an eluate
from an AZO-UbVME-labeled cell lysate was used. Dithionite
concentrations of >10 mm can denature proteins.[27] The re-
ducing conditions used to cleave the azobenzene linker may
Figure 2. Evaluation of the novel probes using UCH-L3. UCH-L3 was incubat-
ed with the different probes (10 mm) for 2 h at 37 8C (left lanes). Biotinylated
proteins were retrieved on streptavidin agarose and released by chemical
cleavage (middle lanes). After cleavage of the linker, beads were boiled to
release remaining biotinylated proteins (right lanes).
Figure 3. Retrieval of DUBs from whole cell lysate using the catch-and-release probe. A) 293T cells were grown
overnight in the presence of [35S]cysteine/methionine. Cells were lysed in NP40 lysis buffer, precleared with strep-
tavidin beads, followed by incubation with the indicated probe (1 mm) at 4 8C. Labeled product was retrieved with
streptavidin agarose, eluted with the relevant elution buffer, and analyzed by SDS-PAGE. B) 293T cells were transi-
ently transfected with YOD1 and treated as in A), though exclusively with the LEV probe. Where indicated, the
eluate was redissolved in NP40 buffer, followed by immuno-retrieval of YOD1.
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thus have reduced protein complexes and/or denatured the
antibody in the course of the second IP. Addition of oxidized
glutathione to quench the excess of sodium dithionite did not
alter the outcome of the experiment (data not shown), and
this issue was not explored further.
Probe delivery in semi-intact cells
In order to efficiently retrieve the protein complexes in which
individual DUBs participate, we devised a strategy that allows
labeling of DUBs in a more physiological setting. To this end,
we chose to deliver the probe in a permeabilized cell system,
instead of incubating a whole cell lysate with an ABP. Cells
were permeabilized through incubation with perfringolysin O
(PFO), a pore-forming toxin that binds cholesterol in the
plasma membrane. We previously documented that after pore
formation, purified compounds can be delivered to the cytosol
by exposure to mild hypotonic conditions, equivalent to 0.5
Hank’s balanced salt solution (HBSS; Figure 1B).[28] 293T cells
(5106) were labeled overnight with [35S]cysteine/methionine,
pelleted, transferred on ice, and resuspended in 0.5 HBSS
(100 mL), PFO (0.1 mm), in the presence or absence of AZO
probe (10 mm, the probe is diluted ~2 upon addition to the
cells). The cells were then incubated at 37 8C, which allows
pore formation to occur, concomitant with an influx of buffer
and delivery of the probe to the
intracellular milieu. After 30 min,
cells were again cooled to 4 8C,
and the cytosol was separated
from the membrane fraction by
mild centrifugation (5 min at
1150g).
This approach offers three
major advantages. First, it allows
labeling of DUBs under more
physiological conditions, that is,
with minimal dilution of cytosol
and—excepting the plasma
membrane—with retention of
organellar integrity, thus increas-
ing the probability of retrieving
meaningful interaction partners.
Second, as the reaction is per-
formed in a small volume, it also
allows for higher concentrations
of probe to be used. Finally, sep-
aration of the soluble fractions
from the membrane fractions
provides useful information on
the localization of any retrieved
DUBs and their associated pro-
teins.
The experiment was per-
formed as described above, and
the recovered fractions were
subjected to denaturation in 1%
SDS, followed by retrieval with
streptavidin agarose (Figure 4A). Denaturation results in re-
lease from the recovered DUBs of any interacting proteins,
thus visualizing only labeled DUBs. We retrieved a large
number of specific proteins—with minimal background—that
distribute over the membrane and soluble fractions. To assess
the integrity of intracellular compartments such as the ER, the
ER luminal protein disulfide isomerase (PDI) was retrieved with
minimal spill-over into the soluble fraction (Figure 4C). To test
whether we could recover DUB complexes in this fashion, the
experiment was repeated, except that the fractions were not
exposed to an SDS-containing buffer (Figure 4B). To minimize
labeling of DUBs post-lysis, a protease inhibitor cocktail (Roche
complete, EDTA free) was added to the NP40 lysis buffer. Using
these conditions, we indeed retrieved a larger number of pro-
teins, but at the expense of increased background.
Detection of chlamydial DUBs in infected cells
Having established proof-of-principle, we focused our atten-
tion on labeling of DUBs in cells infected by C. trachomatis.
HeLa cells were infected with Chlamydia 24 h prior to incuba-
tion with the AZO-UbVME probe. In order to exclusively visual-
ize the chlamydial proteins, the cells were cultured in the pres-
ence of [35S]cysteine/methionine, as well as cycloheximide, to
inhibit host protein synthesis while leaving bacterial protein
Figure 4. Retrieving DUBs from semi-intact cells. A) 293T cells were grown overnight in the presence of [35S]methi-
onine/cysteine. The cells were collected and resuspended in 0.5 HBSS (100 mL) containing PFO (0.1 mm), in the
presence or absence of AZO probe (10 mm). After 30 min at 37 8C, the fractions (P: pellet, S: supernatant) were
separated by mild centrifugation and dissolved in 1% SDS. Labeled protein was retrieved with streptavidin agar-
ose and separated using SDS-PAGE. B) Experiment as in A), but here the fractions were dissolved in NP40 lysis
buffer. C) PDI was retrieved through IP from the lysates produced in A) to serve as a control for separation.
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synthesis intact.[29] The cells were permeabilized using PFO and
incubated with the AZO probe, after which the supernatant
was separated from the pellet fraction by centrifugation. After
analysis by SDS-PAGE, we observed one specific UbVME-reac-
tive protein in the pellet fraction, and three proteins in the su-
pernatant fraction (arrowheads, Figure 5A), one of which has
a molecular weight that corresponds to ChlaDUB2 modified
with UbVME. None of these proteins were detected after inclu-
sion of chloramphenicol, a potent inhibitor of bacterial (but
not host) protein synthesis, further validating them as chlamy-
dial proteins. The chlamydial inclusion remains intact during
this procedure, as the outer membrane protein OMP1 is found
exclusively in the pellet fraction (Figure 5B).
DUB-centered proteomics in semi-intact cells
To establish the identity of the UbVME-reactive proteins in the
Chlamydia-infected semi-intact cells, we subjected the DUBs
and their interacting proteins to LC-MS/MS. We treated unin-
fected HeLa cells as in Figure 4B, separated the chemical
eluate by SDS-PAGE and excised the bands after silver staining
for analysis by LC-MS/MS. In total, 34 DUBs were identified, of
which USP36 had not earlier been found in studies using ubiq-
uitin activity-based probes (Table 1).
Where most DUBs retrieved belong to the USP class of ubiq-
uitin hydrolases, we also observe eight DUBs from the otubain
family, two from the josephin family, and three from the family
of ubiquitin C-terminal hydrolases. These results once again
confirm the remarkable complexity of DUBs expressed by the
typical mammalian cell, underscoring the need to carefully reg-
ulate both ubiquitylation and deubiquitylation reactions.
As our method was devised to allow identification of pro-
teins with which DUBs engage in complex formation, we were
encouraged by the presence of a number of well-studied
DUB–protein complexes. An example is the recovery of most
of the regulatory cap proteins of the 26S proteasome (Table 2).
Other examples of protein complexes retrieved include host
cell factor-1, galectin 7, p97, ras GTPase-binding proteins 1 and
2, WD-repeat containing protein 48 and WD-repeat containing
protein 20, and thioredoxin like protein, which inter-
act with BAP, USP1, ataxin-3, USP10, USP12, and
USP14 or UCH-L5,[4,30] respectively.
In parallel we performed this type of experiment
using Chlamydia-infected cells. As a benchmark, Chla-
DUB1 was identified with 59% and 46% sequence
coverage in the supernatant and pellet fraction, re-
spectively (24 unique peptides in the pellet fraction
and 19 unique peptides in the supernatant fraction,
see Table 1). In addition to ChlaDUB1, we were able
to identify two additional host DUBs previously not
labeled with UbVME: USP33 and TRABID in the Chla-
mydia-infected cells. More importantly, we also iden-
tified ChlaDUB2. This is the first time ChlaDUB2 has
been identified in the course of infection. ChlaDUB2
was identified by mass spectrometry with 14% se-
quence coverage (four unique peptides).
Discussion
Here we describe the development and application
of a catch-and-release strategy to identify DUB–pro-
tein complexes at endogenous levels of expression.
The catch-and-release probes were crafted through
tandem site-specific modification of ubiquitin, which
combined intein chemistry with sortase-mediated
transacylation. This strategy allows for rapid synthesis
of the activity-based probe (UbVME), which is then
modified with a handle of choice at the N terminus,
as illustrated by the production of three different
catch-and-release probes. Neither of these strategies
is limited to modification of ubiquitin, and we could
easily envision the generation of other proteins, simi-
larly modified with two bioorthogonal substituents.
Protein modification with ubiquitin is a complex reaction,
which relies not only on the necessary levels of substrate spe-
cificity (targets are not modified randomly), but also on the
imposition of linkage types that produce ubiquitin chains of
unique topology. While the number of possible substrates and
the types of ubiquitin modifications they carry are endless, the
number of available DUBs that can reverse ubiquitylation and
recycle ubiquitin is not. Approximately 80 DUBs are encoded
Figure 5. The labeling of chlamydial deubiquitylating enzymes. A) HeLa cells infected
with C. trachomatis were labeled with [35S]cysteine/methionine. Host protein synthesis
was inhibited by the addition of cycloheximide. Cells were permeabilized using PFO and
DUBs were labeled with AZO probe (10 mm) and subsequently treated as described
above for uninfected cells. B) The supernatant and pellet fraction of the Chlamydia-infect-
ed cells were immunoblotted (IB) for GAPDH and the chlamydial outer membrane pro-
tein 1 (OMP1).
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by the human genome, not all of which need to be expressed
simultaneously or in the same cell type. Where analyzed, in-
dividual DUBs often harbor specificity for a particular type of
ubiquitin chain,[31] effectively further limiting the number of
available DUBs to hydrolyze ubiquitin and complete the modi-
fication cycle.
To fully understand how deubiquitylation is regulated, and
with it the relevant cell biology, the protein complexes that
harbor this DUB activity must be analyzed at their endogenous
expression level. To this end, we combined our new probes
with a delivery method that enables DUB labeling in the cyto-
sol of PFO-permeabilized cells with minimal dilution of cytosol.
A high concentration of probe is delivered through the PFO-
induced pores to enable labeling under conditions as close to
physiological as possible. This method allowed us to retrieve
36 individual DUBs expressed in HeLa cells, and retrieve pro-
teins in complex with these DUBs, amongst which, for exam-
ple, the regulatory cap of the proteasome (see Table 2), con-
firming earlier observations with a first generation probe.[6]
This value for the number of expressed and active DUBs is
probably representative for different mammalian cell types,
based on the complexity of banding patterns observed in im-
munoblots on HA-UbVME-modified cell extracts.
The sensitivity of our method is further illustrated by the de-
tection of ChlaDUB2 in HeLa cells infected with C. trachomatis,
a DUB whose expression in the course of infection had not
been demonstrated experimentally. It is clear that similar ex-
periments can be undertaken for other intracellular pathogens.
Table 1. Deubiquitinating enzymes retrieved with biotin-AZO-UbVME and identified by MS.
Unique peptides/sequence coverage [%]
Protein Accession number (NCBI) MW [kDa] Uninfected HeLa cells Chlamydia-infected cells
Pellet Supernatant Pellet Supernatant
USPs
USP1 (UBP) 31543910 88 16/23 12/14 1/1.3 14/19
USP3 (SIH003, UBP) 55770886 59 15/32 3/6.5 12/26 4/11
USP4 (UNP, Unph) 40795665 109 8/13 1/1 15/18
USP5 (ISOT1) 148727247 93 40/54 41/47
USP7 (HAUSP, TEF1) 150378533 128 47/37 55/41 23/20 63/52
USP8 (HumORF8; UBPY) 190684690 128 26/19 24/21 9/11 11/13
USP10 (UBPO) 119220605 87 18/32 28/38 10/15 22/29
USP11 (UHX1) 24234683 110 15/19 4/7.4
USP12 (UBH1, USP12L1) 301500675 43 4/13 7/13 4/13 5/16
USP13 (IsoT-3, ISOT3) 215598688 97 5/6.8
USP14 (TGT) 4827050 56 29/56 33/67 22/44 25/45
USP15 (UNPH4, UNPH-2) 355330276 112 16/17 57/57 1/0.92 34/39
USP16 (UBP-M) 5454156 94 9/9.7 23/33 14/8.6 14/10
USP19 (ZMYND9) 312596875 151 5/4.3 25/20 8/5.2 14/9.9
USP24 260064009 294 7/3.4 1/0.46
USP25 (USP21) 50312666 122 4/4.5 4/2.7
USP28 16507200 122 2/2.2 2/2.1 4/4.3 15/21
USP33 (VDU1) 42516561 94 4/7.6
USP36 (DUB1) 122114651 123 1/1.4 9/8.5 7/6.9
USP47 (TRFP) 1774197 147 1/1.8 23/22 1/1.5 17/9.7
USP48 (RAP1GA1, USP31) 52630449 119 3/3.6 7/5.3
USP9X (DFFRX, FAF, FAM) 145309309 292 30/13 17/6
CYLD1 (BRSS, CDMT, EAC, MFT1, SBS, TEM, USPL2) 109637774 107 4/4.1
UCHs
BAP1 (HUCEP-13, hucep-6, TPDS, UCHL2) 4757836 80 6/7.5 3/3.6 13/9.7
UCHL3 (UCH-L3) 5174741 26 5/29 19/62 4/24 21/62
UCHL5 (CGI-70, INO80R, UCH37) 7706753 38 18/58 22/72 11/33 23/66
Josephins
JOS (ATX3, JOS, MJD, MJD1, SCA3) 13518019 41 2/6.4 10/35 1/3.3 9/31
JOS2 19923879 21 1/6.4 2/7.4
OTU domain
OTU1 (YOD1, DUBA8, OTUD2, PRO0907) 62751964 38 10/20 4/12
OTUB1 (HSPC263) 109148508 31 3/13 4/14
OTUB2 12962939 27 2/11
OTUD3 (UBA4) 149192871 45 3/8.5 4/8.8 3/9.5
OTUD5B (DUBA) 209977019 60 5/11 2/3.2
OTUD6B (GI-77, DUBA5) 157364937 37 4/19 14/47 1/4.3 8/23
OTUD7B (CEZANNE, ZA20D1) 118026942 93 2/3.7 19/32 12/9.3
ZRANB1 (TRABID) 110815809 81 2/4.1
VCIP1 (DUBA3, VCIP135) 36029914 134 2/2.3
Chlamydial DUBs
ChlaDUB1 166154214 45 24/59 19/46
ChlaDUB2 166154213 38 4/14
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Our analysis here is limited to snapshots of DUB activity in
a population of cells. The nature of the experimental set-up,
which does not rely on genetic expression of the ABP, allows
for a more dynamic approach. How does the cellular ubiquitin
machinery react to external changes? As an example we dem-
onstrated the expression of active DUBs by the pathogen
C. trachomatis, as assessed by ABP labeling. Our results suggest
that the cellular environment in which Chlamydia seeks to sur-
vive and expand necessitates the delivery of different bacterial
countermeasures: not only is ChlaDUB1 expressed, but also
ChlaDUB2, raising the interesting question of how these chla-
mydial enzymes differ in their substrate specificity from the
host set of DUBs, and of course the identity of their preferred
targets. In the absence of a genetic system with which to
ablate either or both of the genes that encode the ChlaDUBs,
their contribution to successful completion of the chlamydial
life cycle will have to await the development of such tools.
Experimental Section
Preparation of G3UbVME: Ubiquitin (1–75) N-terminally fused to
a thrombin cleavage site followed by GGG (MGSSHHHHHHSSGL-
VPRGGG) and C-terminally fused to an intein was cloned into
pTYB2. The vector was transformed into BL21(DE3)pLysS. The ubiq-
uitin-intein constructed was expressed, purified and converted into
the UbVME adduct as previously described for HA-tagged
UbVME.[6] Cleaving the thrombin sequence by using a Thrombin
CleanCleave kit (Sigma–Aldrich) exposed the N-terminal Gly-Gly-Gly
sequence.
Introduction of the biotin-cleavable linker: G3UbVME (58 mm final
concentration) was incubated with Sortase A of Staphylococcus
aureus [150 mm final concentration, 4.5 stock in Tris (50 mm),
pH 7.4, NaCl (150 mm)] and biotin-cleavable linker-LPETGG pep-
tides 1–3 (0.5 mm final concentration, 10 stock, for synthesis see
the Supporting Information) in sortase reaction buffer [Tris
(50 mm), pH 7.4, NaCl (150 mm), CaCl2 (10 mm)] . The resulting mix-
ture was incubated at 37 8C for 3 h, acidified by the addition of 1%
Table 2. Interacting proteins retrieved with Biotin-AZO-UbVME and identified using MS.
Unique peptides/sequence coverage [%]
Protein Accession number (NCBI) MW [kDa] Uninfected HeLa cells Chlamydia-infected cells
Pellet Supernatant Pellet Supernatant
Proteasome subunits
a subunits
PSMA1 23110935 30 4/15 34/44 38/51
b subunits
PSMB5 4506201 28 2/8.7 2/7.6 1/3.8
26S ATPase
PSMC1; p56; S4 24430151 49 13/31 20/45 3/6.1 7/21
PSMC2; MSS1; S7 4506209 49 16/42 25/48 7/12 20/38
PSMC3; TBP1 21361144 49 13/36 28/62 9/21 8/12
PSMC4; MIP224; S6 5729991 47 8/23 22/39 3/6.5 11/19
PSMC5; p45; S8 312596881 45 15/48 27/69 3/6.3 18/43
PSMC6; p42 195539395 46 17/49 18/50 2/4 19/34
26S non-ATPase
PSMD1; P112; S1 25777600 106 16/23 34/44 19/24 38/51
PSMD2; P97; S2 25777602 100 23/30 28/39 21/28 33/36
PSMD3; P58; S3 25777612 61 15/30 17/31 8/18 13/26
PSMD4; S5A 5292161 41 16/41 15/45 10/34 16/45
PSMD5; S5B 4826952 56 3/7.1 16/38 12/31
PSMD6; S10 7661914 46 9/28 9/26 1/2.3 10/31
PSMD7; P40; S12 25777615 37 12/43 10/40 8/22 12/45
PSMD8; p31; S14 156631005 40 4/14 2/7.1 2/5.4 2/12
PSMD9; p27 18543329 25 5/23 7/34 1/4
PSMD10; p28 4506217 24 6/35 4/23
PSMD11; p44.5; S9 28872725 47 11/28 14/35 4/6.9 9/19
PSMD12; p55 4506221 53 6/12 9/19 2/4.8 4/9.6
PSMD13; p40.5; S11 157502193 43 7/21 5/14 2/4.8 9/28
PSMD14 5031981 35 3/16 5/21 3/6.5 2/9.4
ADRM1; hRpn13 28373192 (+1) 42 12/19 14/25 3/5.4 11/17
Proteasome associated
PAAF1; PAAF; WDR71 13376751 42 10/28 8/18 5/16
Other interactors
HCF-C1 98986457 209 15/4.9 1/1.2
galectin 7 109948279 (+1) 15 5/45
VCP; p97 6005942 89 31/43 13/22 4/5.3 3/6.0
G3BP-1 38327552 (+1) 52 8/18 10/21
G3BP-2 19923399 (+1) 54 4/9.8 6/12
WD repeat-containing protein 48 18874090 76 33/47 26/41 22/31 22/25
WD repeat-containing protein 20 isoform 7 334848139 67 6/13 4/8.5 3/4 2/4.7
thioredoxin-like protein 1 4759274 32 13/55 4/19
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TFA in H2O and purified by reversed-phase HPLC (30!45% B over
20 min, 3 mLmin1; solvent A=0.1% aqueous trifluoroacetic acid,
solvent B=MeCN). The resulting purified protein was neutralized
with saturated aq. NaHCO3, concentrated in vacuo, redissolved in
H2O and quantified by gel-electrophoresis. The protein was ana-
lyzed by LC-MS. Biotin-AZO-UbVME: tR=7.76 min; linear gradient
5!45% B in 20 min; ESI-MS: m/z 10140 [M+H]+ . Biotin-LEV-
UbVME: tR=7.57 min; linear gradient 5!45% B in 20 min; ESI-MS:
m/z 10244 [M+H]+ . Biotin-CLB-UbVME: tR=7.30 min; linear gradi-
ent 5!45% B in 20 min; ESI-MS: m/z 9928 [M+H]+ .
Antibodies, cell lines, constructs and reagents: Antibodies
against YOD1 and PDI were raised in rabbits against purified whole
protein and have been described.[26] GAPDH antibody was ob-
tained from Abcam. HEK293T and HeLa cells were purchased from
the American Type Culture Collection. Cells were cultured in Dul-
becco’s modified Eagle’s medium (DMEM).
The YOD1 construct in a pcDNA3.1(+) plasmid used for transfec-
tion experiments has been described.[26] HEK293T cells were transi-
ently transfected using Trans-IT (Takara Mirus Bio, Madison, WI)
according to the manufacturer’s instructions. Cycloheximide, aniso-
mycin and chloramphenicol were obtained from Sigma–Aldrich.
Metabolic labeling, immunoprecipitations and SDS-PAGE: To
achieve steady-state protein labeling, cells were incubated over-
night with 200 mCi of [35S]methionine/cysteine (PerkinElmer) per
mL of methionine/cysteine-free DMEM supplemented with 10%
dialyzed inactivated fetal serum (IFS) at 37 8C.
Cells were either lysed in NP40 lysis buffer [0.5% NP40, Tris·HCl
(10 mm), NaCl (150 mm), MgCl2 (5 mm), pH 7.4] supplemented
with a complete protease inhibitor cocktail (Roche) where indicat-
ed, or in 1% SDS. Prior to immunoprecipitation, the SDS lysate was
diluted to 0.1% SDS in NP40 lysis buffer.
Immunoprecipitation was performed using either streptavidin agar-
ose (30 mL, Sigma) or immobilized Protein A (IPA 300, 30 mL, Repli-
gen) with the relevant antibodies.
Protein samples were separated by SDS-PAGE and visualized by
autoradiography.
Immunoblotting: Protein samples were separated by SDS-PAGE,
blotted onto a PVDF membrane and probed with the relevant anti-
bodies.
Probe delivery to semi-intact cells: Cells were collected on ice,
and resuspended in 0.5 HBSS (100 mL, containing purified PFO
(0.1 mm)—for preparation of PFO, see ref. [28]). After addition of
the relevant probe, cells were incubated 37 8C for 30 min. After
30 min, the cells were returned to 4 8C and fractions were separat-
ed by centrifugation at 1150g for 5 min. The supernatant fraction
was withdrawn, after which the pellet fraction was washed in HBSS
followed by another round of centrifugation.
Labeling of HeLa cells infected with Chlamydia trachomatis L2/
434/Bu: HeLa cells and C. trachomatis L2/434/Bu were propagated
and stored as previously described.[11] [35S]methionine/cysteine la-
beling and PFO permeabilization were performed analogous to the
protocol described by Kleba et al.[29] In brief, HeLa cells were infect-
ed with Chlamydia (multiplicity of infection (MOI) of 3–10), and cul-
tured at 37 8C. After 20 h, the DMEM was replaced with methio-
nine/cysteine-free DMEM supplemented with 10% dialyzed IFS, cy-
cloheximide (225 mgmL1), anisomycin (30 mgmL1) and [35S]methi-
onine/cysteine (200 mCi). As a control, bacterial proteins synthesis
was blocked with chloramphenicol (100 mgmL1). The cells were
incubated at 37 8C for 4 h. AZO-UbVME was introduced by permea-
bilization with PFO as described in the general method above.
Mass-spectrometry-based analysis of the labeled proteins: Pro-
teins were labeled, immunoprecipitated and released from the af-
finity matrix as described above. The retrieved proteins were sepa-
rated on a gel and visualized using silver staining. Gel lanes were
excised; the proteins were reduced, alkylated and digested with
trypsin overnight at 37 8C. The resulting tryptic fragments were
extracted, concentrated and separated using a Waters NanoAcquity
HPLC equipped with a self-packed Jupiter C18 column (3 mm,
0.07510 mm) using standard reversed-phase gradients (isocratic
1% B buffer for 1 min, 250 nLmin1 with increasing B buffer con-
centrations to 15% B at 14 min, 27% B at 21 min and 40% B at
24.5 min. Buffer A=1% formic acid in water and buffer B=1%
formic acid in acetonitrile). The eluted peptides were analyzed
using a Thermo LQT linear ion-trap mass spectrometer (nanospray
configuration) operated in a data-dependent manner. The SEQUEST
database was used to correlate the fragmentation spectra. Scaf-
fold 3 was used to analyze and report the resulting data.
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